Discovery & Aerogen tackle respiratory disease:
This article was originally published in Clinica
Discovery Laboratories, of Doylestown, Philadelphia, and Aerogen will evaluate Aerogen's Aeroneb Pro system as a means for pulmonary delivery of Discovery's Surfaxin humanised lung surfactant in hospitalised, mechanically ventilated patients. Aerosolised surfactant therapies, which are used in patients with respiratory disease to improve the lungs' ability to absorb oxygen, represent a worldwide market of $5bn, the companies note. Aerogen, of Mountain View, California, believes that the collaboration could markedly improve respiratory drug therapy in the critical care setting.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.